Commissioner Gottlieb and the Crusade Against Opioid Abuse: Baptism by Fire J. Rick Turner Editorial 30 December 2017 Pages: 400 - 403
Using Individual Experiences With Experimental Medications to Predict Medication-Taking Behavior Postauthorization: A DIA Study Endpoints Workstream Matthew ReaneyColleen A. McHorneyChad Gwaltney Clinical Trials: Analytical Report 30 December 2017 Pages: 404 - 415
Center for Drug Evaluation and Research Perspective on Quality in Clinical Trials Stephanie ShapleyJacqueline O’ShaughnessyJanet Woodcock Clinical Trials: Commentary 30 December 2017 Pages: 416 - 418
Key Elements of Pharmacoinformatics for the Degrees of Bachelor and Master of Pharmacy Imas Nur Amelia ZainalNur Amirah Abd KarimQi Ying Lean Educational Perspectives: Analytical Report 30 December 2017 Pages: 419 - 425
Clarifying the Discussion Points in New Drug Application Reviews for Approval in Japan by a Government Advisory Council Yasuyuki HattoriHideki HanaokaYoshiaki Uyama Global Perspectives: Original Research 30 December 2017 Pages: 426 - 430
Typographic Changes in Package Leaflets of the European Union Based on the Example of German Versions Between 2005 and 2015 Jörg FuchsSaskia KraftMichael Reiche Global Perspectives: Original Research 30 December 2017 Pages: 431 - 438
Compliance of Community Pharmacists and Private General Medical Practitioners With Malaysian Laws on Poisons and Sale of Drugs Chuo Yew TingShing Chyi LooAbu Hassan Alshaari Abd Jabar Global Perspectives: Original Research 30 December 2017 Pages: 439 - 445
Trans-Pacific Partnership Agreement and Its Impact on Accessibility and Affordability of Medicines: A Meta-synthesis Yan Yee YapChe Pui WongTahir Mehmood Khan Global Perspectives: Review 30 December 2017 Pages: 446 - 459
Patient Centricity and Pharmaceutical Companies: Is It Feasible? Danie du PlessisJohn-Kenneth SakeNeil Bertelsen Policy: Review Open access 30 December 2017 Pages: 460 - 467
One Patient Is Not One Condition: Delivering Patient-Centered Care to Those With Multiple Chronic Conditions Jan LiskaAnne Beal Policy: Commentary 30 December 2017 Pages: 468 - 470
The Landscape of Contract Manufacturing of Sterile Injectable Drugs: Who Is Making What, Where, and for Whom William LiuMarta E. Wosinska Product Development & Innovation: Original Research 30 December 2017 Pages: 471 - 479
Mobile Medical Applications for Dosage Recommendation, Drug Adverse Reaction, and Drug Interaction: Review and Comparison Nur Amirah ApidiMuthu Kumar MurugiahLong Chiau Ming Product Development & Innovation: Original research 30 December 2017 Pages: 480 - 485
The Enigma of Pharmacovigilance of Patient Support Programs: A Survey of Marketing Authorization Holders in Europe Jamie Michelle PortnoffDavid John Lewis Regulatory Science: Original Research 30 December 2017 Pages: 486 - 493
Pre-approval Access Terminology: A Cause for Confusion and a Danger to Patients Laura L. KimberlyMarc M. BeuttlerAlison Bateman-House Regulatory Science: Original Research 30 December 2017 Pages: 494 - 500
Structured Benefit-Risk Assessment Across the Product Lifecycle: Practical Considerations Meredith Y. SmithIsma BenattiaQi Jiang Regulatory Science: Original Research 30 December 2017 Pages: 501 - 508
Breakthrough Therapy Designation: CDER Analysis of Requests 4 Years Into the Program Ryan ConradKimberly TaylorAmy Bertha Regulatory Science: Original Research 30 December 2017 Pages: 509 - 515
Patient-Centered Therapy Development for Myotonic Dystrophy: Report of the Myotonic Dystrophy Foundation–Sponsored Workshop Sharon HesterleeShashi AmurMolly White Special Populations: Meeting Report 30 December 2017 Pages: 516 - 522